Skip to content

Management

Sarah Fredriksson

Sarah Fredriksson

Chief Executive Officer

In current position since 2017.

Education: Ph.D. in Biochemistry in 1999 and M.Sc. in Chemistry in 1993 from the Faculty of Engineering (LTH), Lund University.

Experience and prior assignments: Sarah Fredriksson founded Genovis AB and during her time as CEO for more than 15 years, Genovis’ product concept was developed and launched and the company was listed on First North, Nasdaq OMX Nordic. She has many years of experience from research and development in biotech from both academia and industry. For several years now, she has been active as an entrepreneur, CEO and board member in unlisted and listed life science companies such as Respiratorius AB (publ), Edvince AB, Genovis AB (publ), Lunds University and SwedenBIO AB.

Other current assignments: Board member of LU Holding, Faculty of Engineering (LTH).

Born: 1968

Holdings: 2,300 shares.

Carina Eldh

Carina Eldh

Chief Controlling Officer

In current position since 2019, employed since 2011.

Education: Secondary school economics 1989, graduate in accounting 1999, certified controller 2021.

Experience and prior assignments: Carina Eldh has more than 20 years of experience in accounting, auditing and taxation and has previously held positions at KPMG and other auditing and advisory firms, the Swedish Tax Agency and Öresundskraft.

Other current assignments: None

Born: 1970

Holdings:

Anneli Hällgren

Anneli Hällgren

Senior Director Preclinical Development

In current position since 2022.

Education: B.Sc. in Pharmacy and Ph.D. in Physiology from Uppsala University.

Experience and prior assignments: Anneli Hällgen has more than 25 years of experience from drug development with emphasis on nonclinical documentation for clinical trials and marketing applications within several therapeutic areas. Her career began at AstraZeneca, where she worked as a safety pharmacologist and preclinical project manager. Since then, she has held leading positions at companies such as KaroBio, Biolipox, Melacure Therapeutics and most recently she has worked as a consultant in preclinical drug discovery.

Other current assignments: None

Born: 1965

Holdings:

Martin Johansson

Martin Johansson

Senior Director Medicinal Chemistry

In current position since 2019.

Education: Ph.D. in Organic Chemistry 2002, Associate Professor in Organic Chemistry 2007, and Master’s degree in Chemical Engineering 1997, Lund University.

Experience and prior assignments: Martin Johansson has been involved with Aqilion since 2012 as project manager for the former project company Glactone Pharma AB. He has 20 years of experience in medicinal chemistry and preclinical drug discovery and development. Previously, he has held the position of Chief Scientific Officer at Respiratorius AB and Senior Research Scientist at AstraZeneca, Discovery R&D.

Other current assignments: Board member of Selcis Biopharma AB.

Born: 1971

Holdings:

Fredrik Lindgren

Fredrik Lindgren

Vice President, Chief Business Officer

In current position since 2018.

Education: Ph.D. in Chemistry, 1994 and B.Sc. in Chemistry 1989, Umeå University.

Experience and prior assignments: Fredrik Lindgren’s background is in the pharmaceutical industry, with experience from key positions in areas such as business development processes at AstraZeneca and LEO Pharma. among others. Most recently he held the position of Senior Director, Head of Global Business Development, at LEO Pharma.

Other current assignments: None

Born: 1967

Holdings:

Johan Lund

Johan Lund

Vice President, Chief Scientific Officer

In current position since 2021.

Education: M.D., Ph.D. 1986 Karolinska Institutet; Post-doctoral studies 1987-1989 UT Southwestern Medical Center, Texas; Associate Professor 1990 Karolinska Institutet; Professor 1996 University of Bergen.

Experience and prior assignments: Dr. Johan Lund has many years of experience from executive positions in pharmaceutical research and development. He is the CEO and founder of KyNexis Medicine Development AB and the founder of MBS Pharma AB. Most recently, he was Vice President of Translational R&D at Celgene, in Cambridge, Massachusetts, USA, with responsibility for early research and development in inflammation and immunology. Previous positions include Chief Scientific Officer, Immunoscience Research Unit at Pfizer, Cambridge, Massachusetts, as well as 14 years at AstraZeneca in executive positions in Sweden and the UK as Vice President CNS & Pain Innovative Medicines Science and Vice President Respiratory and Inflammation Research.

Other current assignments: Chairman of AQILION AB. Board member of Olink Proteomics AB, Genagon Therapeutics AB, NEOGAP AB, Pelago AB, KyNexis Medicine Development AB and MBS Pharma AB.

Born: 1957

Holdings:

Jan Törnell

Jan Törnell

Vice President, Chief Medical Scientist

In current position since 2018.

Education: Medical degree, University of Gothenburg, 1985; Ph.D. in Physiology, Faculty of Medicine, Gothenburg, 1990; and Associate Professor in Physiology, 1992.

Experience and prior assignments: Jan Törnell has been involved with Aqilion/P.U.L.S. since 2012 through board positions in portfolio companies, as project manager/CEO and as an innovator. He also has many years of experience in executive positions in the pharmaceutical industry internationally. He has previously held the position of Global Vice President Strategy, Oncology & Infection and Global VP Translational Science at AstraZeneca and was Professor at the Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg.

Other current assignments: Chairman of the Board of Glactone Pharma AB, LIDDS AB (publ) and Innoext AB; Board member of Diaprost AB and Abliva AB (publ).

Born: 1960

Holdings: 1,588 shares.

Torgeir Vaage

Torgeir Vaage

Vice President, Chief Financial Officer

In current position since 2020.

Education: Degree in business administration from the Norwegian School of Economics (NHH) and a Ph.D. in Business Administration from the University of California, Berkeley, USA.

Experience and prior assignments: Torgeir Vaage has more than 20 years of combined experience in the life science industry and the financial sector. In recent years, he has worked in Denmark and Norway as CFO and CEO for several small biotech companies with a focus on pharmaceuticals. Prior to that he was a senior analyst and partner at ABG Sundal Collier, senior capital analyst at Handelsbanken and management consultant at AT Kearney in Oslo.

Other current assignments: CFO of Initiator Pharma and Acesion Pharma.

Born: 1964

Holdings: